Oncolytic Adenovirus

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle, Emiliano Calvo

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 20; DOI: 10.1186/s40425-019-0510-7
Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site
Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat, Vincenzo Cerullo

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 174; DOI: 10.1186/s40425-019-0644-7
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
Jana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, Maria D. Ramos, Martí Farrera-Sal, Ramon Alemany

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 19; DOI: 10.1186/s40425-019-0505-4
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
Tuuli Ranki, Sari Pesonen, Akseli Hemminki, Kaarina Partanen, Kalevi Kairemo, Tuomo Alanko, Johan Lundin, Nina Linder, Riku Turkki, Ari Ristimäki, Elke Jäger, Julia Karbach, Claudia Wahle, Matti Kankainen, Charlotta Backman, Mikael von Euler, Elina Haavisto, Tiina Hakonen, Raita Heiskanen, Magnus Jaderberg, Juuso Juhila, Petri Priha, Laura Suoranta, Lotta Vassilev, Antti Vuolanto, Timo Joensuu

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 17; DOI: 10.1186/s40425-016-0121-5
Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform
Cristian Capasso, Mari Hirvinen, Mariangela Garofalo, Dmitrii Romaniuk, Lukasz Kuryk, Teea Sarvela, Andrea Vitale, Maxim Antopolsky, Aniket Magarkar, Tapani Viitala, Teemu Suutari, Alex Bunker, Marjo Yliperttula, Arto Urtti, Vincenzo Cerullo

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P333; DOI: 10.1186/2051-1426-3-S2-P333
Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
Riikka Havunen, Mikko Siurala, Suvi Parviainen, Simona Bramante, Dipongor Saha, Siri Tähtinen, Markus Vähä-Koskela, Michael Behr, Dirk Nettelbeck, Anja Ehrhardt, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P41; DOI: 10.1186/2051-1426-3-S2-P41
Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance
Siri Tähtinen, Susanna Grönberg-Vähä-Koskela, Dave Lumen, Maiju Merisalo-Soikkeli, Mikko Siurala, Anu J Airaksinen, Markus Vähä-Koskela, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P315; DOI: 10.1186/2051-1426-3-S2-P315
"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours
Brian R Champion, Prithvi Kodialbail, Sam Illingworth, Nalini Rasiah, Dan Cochrane, John Beadle, Kerry Fisher, Alice CN Brown

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P46; DOI: 10.1186/2051-1426-2-S3-P46
Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients
Mamun Majumder, Ashwini Kumar, Caroline Heckman, Matti Kankainen, Sari Pesonen, Elke Jäger, Julia Karbach, Timo Joensuu, Kalevi Kairemo, Kaarina Partanen, Tuomo Alanko, Akseli Hemminki, Charlotta Backman, Kasper Dienel, Mikael von Euler, Tiina Hakonen, Juuso Juhila, Tuuli Ranki, Lotta Vassilev, Antti Vuolanto, Magnus Jaderberg

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P230; DOI: 10.1186/2051-1426-2-S3-P230

Log in using your username and password

Main menu

Log in using your username and password

You are here

Oncolytic Adenovirus